Search

Your search keyword '"Malard, F"' showing total 478 results
Start Over Author "Malard, F"
478 results on '"Malard, F"'

2. High-dose chemotherapy with autologous stem cell transplants in adult primary non-seminoma mediastinal germ-cell tumors. A report from the Cellular Therapy and Immunobiology working party of the EBMT

Author

Secondino, S., Badoglio, M., Rosti, G., Labopin, M., Delaye, M., Bokemeyer, C., Seidel, C., Kanfer, E., Metafuni, E., Finke, J., Bouhris, J.-H., Kosmas, C., Malard, F., Pagani, A., Kuball, J., Koehl, U., Ruggeri, A., De Giorgi, U., and Pedrazzoli, P.

Published
2024
Full Text
View/download PDF

3. Choice of commercially available CAR-T cell products for r/r DLBCL & PMBCL in Europe: a survey on behalf of the cellular therapy & immunobiology working party (CTIWP) of the EBMT

Author

Novak, U., Mooyaart, J. E., Daskalakis, M., Scheid, C., Gabellier, L., Yakoub-Agha, I., Ram, R., Forcade, E., Lopez-Corral, L., Nicholson, E., Galli, Eugenio, Stolzel, F., Bethge, W., Wagner-Drouet, E. M., Hoogenboom, J. D., Mielke, S., Arber, C., Simonetta, F., Chabannon, C., Kuball, J., Ruggeri, Annalisa, Malard, F., Galli E. (ORCID:0000-0002-2839-916X), Ruggeri A., Novak, U., Mooyaart, J. E., Daskalakis, M., Scheid, C., Gabellier, L., Yakoub-Agha, I., Ram, R., Forcade, E., Lopez-Corral, L., Nicholson, E., Galli, Eugenio, Stolzel, F., Bethge, W., Wagner-Drouet, E. M., Hoogenboom, J. D., Mielke, S., Arber, C., Simonetta, F., Chabannon, C., Kuball, J., Ruggeri, Annalisa, Malard, F., Galli E. (ORCID:0000-0002-2839-916X), and Ruggeri A.

Abstract

Since summer 2018, three CAR-T cell products have been approved by the EMA to treat aggressive B-cell lymphomas, DLBCL, either de novo or tFL and PMBCL: tisagenlecleucel (tisacel), axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel) [1–3]. Tisa-cel, axi-cel, and liso-cel are approved for the treatment of adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) (and primary mediastinal large B-cell lymphoma (PMBCL) for axi-cel and liso-cel). More recently, axi-cel and liso-cel were additionally approved for the treatment of adult patients with DLBCL and high-grade B-cell lymphoma (HGBL) (and PMBCL for liso-cel) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy [2, 4, 5]. While the exact labelings of these products are different, there is a considerable overlap in product attributes and indications. There is so far no formal recommendations by medical experts or societies regarding the choice of one CAR-T cell product over another and no randomized trial addressed nor is likely to address the issue of the choice of the CAR-T cell products. Therefore, to evaluate the real-world practices of the usage of CAR-T cells in aggressive lymphomas and capture the criteria used by centers to guide their choice of a product for a given patient, we conducted a survey on behalf of the Cellular Therapy and Immunobiology Working Party (CTIWP) of the EBMT.

Published
2024

4. High-dose chemotherapy with autologous stem cell transplants in adult primary non-seminoma mediastinal germ-cell tumors. A report from the Cellular Therapy and Immunobiology working party of the EBMT

Author

CTI Kuball, MS Hematologie, Cancer, Infection & Immunity, Regenerative Medicine and Stem Cells, Secondino, S, Badoglio, M, Rosti, G, Labopin, M, Delaye, M, Bokemeyer, C, Seidel, C, Kanfer, E, Metafuni, E, Finke, J, Bouhris, J-H, Kosmas, C, Malard, F, Pagani, A, Kuball, J, Koehl, U, Ruggeri, A, De Giorgi, U, Pedrazzoli, P, EBMT Cellular Therapy & Immunobiology WP, CTI Kuball, MS Hematologie, Cancer, Infection & Immunity, Regenerative Medicine and Stem Cells, Secondino, S, Badoglio, M, Rosti, G, Labopin, M, Delaye, M, Bokemeyer, C, Seidel, C, Kanfer, E, Metafuni, E, Finke, J, Bouhris, J-H, Kosmas, C, Malard, F, Pagani, A, Kuball, J, Koehl, U, Ruggeri, A, De Giorgi, U, Pedrazzoli, P, and EBMT Cellular Therapy & Immunobiology WP

Published
2024

9. French early nationwide idecabtagene vicleucel chimeric antigen receptor T‐cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real‐world IFM study from the DESCAR‐T registry.

Author

Ferment, B., Lambert, J., Caillot, D., Lafon, I., Karlin, L., Lazareth, A., Touzeau, C., Leleu, X., Moya, N., Harel, S., Perrot, A., Bories, P., Vincent, L., Lamure, S., Mohty, M., Malard, F., Manier, S., Yakoub‐Agha, I., Schiano De Colella, J.‐M., and Brisou, G.

Subjects
CYTOKINE release syndrome, BISPECIFIC antibodies, CHIMERIC antigen receptors, PATIENT experience, MULTIPLE myeloma
Abstract

Summary: Idecabtagene vicleucel (ide‐cel), a chimeric antigen receptor T‐cell therapy targeting B‐cell maturation antigen (BCMA), received early access program (EAP) authorization in France in April 2021 for relapsed/refractory multiple myeloma (RRMM). We conducted a real‐world registry‐based multicentre observational study in 11 French hospitals to evaluate ide‐cel outcomes. Data from 176 RRMM patients who underwent apheresis between June 2021 and November 2022 were collected from the French national DESCAR‐T registry. Of these, 159 patients (90%) received ide‐cel. Cytokine release syndrome occurred in 90% with 2% grade ≥3, and neurotoxicity occurred in 12% with 3% grade ≥3. Over the first 6 months, the best overall response and ≥complete response rates were 88% and 47% respectively. The median progression‐free survival (PFS) from the ide‐cel infusion was 12.5 months, the median overall survival (OS) was 20.8 months and the estimated OS rate at 12 months was 73.3%. Patients with extra‐medullary disease (EMD) had impaired PFS (6.2 months vs. 14.8 months). On multivariable analysis, EMD and previous exposure to BCMA‐targeted immunoconjugate or T‐cell‐redirecting GPRC5D bispecific antibody were associated with inferior PFS. Our study supports ide‐cel's feasibility, safety and efficacy in real‐life settings, emphasizing the importance of screening for EMD and considering prior treatments to optimize patient selection. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Groundwater is a hidden global keystone ecosystem

Author

Saccò, M., Mammola, S., Altermatt, F., Alther, R., Bolpagni, R., Brancelj, A., Brankovits, D., Fišer, C., Gerovasileiou, V., Griebler, C., Guareschi, S., Hose, G.C., Korbel, K., Lictevout, E., Malard, F., Martínez, A., Niemiller, M.L., Robertson, A., Tanalgo, K.C., Bichuette, M.E., Borko, S., Brad, T., Campbell, M.A., Cardoso, P., Celico, F., Cooper, S.J.B., Culver, D., Di Lorenzo, T., Galassi, D.M.P., Guzik, M.T., Hartland, A., Humphreys, W.F., Ferreira, R.L., Lunghi, E., Nizzoli, D., Perina, G., Raghavan, R., Richards, Z., Reboleira, A.S.P.S., Rohde, M.M., Sánchez Fernández, D., Schmidt, Susanne Isabel, van der Heyde, M., Weaver, L., White, N.E., Zagmajster, M., Hogg, I., Ruhi, A., Gagnon, M.M., Allentoft, M.E., Reinecke, R., Saccò, M., Mammola, S., Altermatt, F., Alther, R., Bolpagni, R., Brancelj, A., Brankovits, D., Fišer, C., Gerovasileiou, V., Griebler, C., Guareschi, S., Hose, G.C., Korbel, K., Lictevout, E., Malard, F., Martínez, A., Niemiller, M.L., Robertson, A., Tanalgo, K.C., Bichuette, M.E., Borko, S., Brad, T., Campbell, M.A., Cardoso, P., Celico, F., Cooper, S.J.B., Culver, D., Di Lorenzo, T., Galassi, D.M.P., Guzik, M.T., Hartland, A., Humphreys, W.F., Ferreira, R.L., Lunghi, E., Nizzoli, D., Perina, G., Raghavan, R., Richards, Z., Reboleira, A.S.P.S., Rohde, M.M., Sánchez Fernández, D., Schmidt, Susanne Isabel, van der Heyde, M., Weaver, L., White, N.E., Zagmajster, M., Hogg, I., Ruhi, A., Gagnon, M.M., Allentoft, M.E., and Reinecke, R.

Abstract

Groundwater is a vital ecosystem of the global water cycle, hosting unique biodiversity and providing essential services to societies. Despite being the largest unfrozen freshwater resource, in a period of depletion by extraction and pollution, groundwater environments have been repeatedly overlooked in global biodiversity conservation agendas. Disregarding the importance of groundwater as an ecosystem ignores its critical role in preserving surface biomes. To foster timely global conservation of groundwater, we propose elevating the concept of keystone species into the realm of ecosystems, claiming groundwater as a keystone ecosystem that influences the integrity of many dependent ecosystems. Our global analysis shows that over half of land surface areas (52.6%) has a medium-to-high interaction with groundwater, reaching up to 74.9% when deserts and high mountains are excluded. We postulate that the intrinsic transboundary features of groundwater are critical for shifting perspectives towards more holistic approaches in aquatic ecology and beyond. Furthermore, we propose eight key themes to develop a science-policy integrated groundwater conservation agenda. Given ecosystems above and below the ground intersect at many levels, considering groundwater as an essential component of planetary health is pivotal to reduce biodiversity loss and buffer against climate change.

Published
2023

14. Global groundwater in the Anthropocene

Author

Malard, F., Griebler, C., Rétaux, S., Kretschmer, D., Wachholz, Alexander, Reinecke, R., Malard, F., Griebler, C., Rétaux, S., Kretschmer, D., Wachholz, Alexander, and Reinecke, R.

Abstract

Groundwater is a fundamental resource of freshwater for both humans and ecosystems. In the Anthropocene, unsustainable use threatens groundwater in many parts of the world. This chapter provides a global perspective on this valuable and hidden resource in three aspects. First, we discuss groundwater availability and the worldwide distribution of groundwater, its interaction with surface water bodies, and show how a changing climate affects its replenishment. In the second part of this chapter, we discuss two frameworks of sustainable groundwater use, i.e., the U.N.’s Sustainable Development Goals and the planetary boundaries concept. Third, we summarize global threats to groundwater from a quantity and quality perspective. Current research on depletion, seawater intrusion, and groundwater quality deterioration is outlined and discussed. Groundwater is the largest source of unfrozen freshwater, but the Anthropocene has already left its imprints on this pivotal resource due to unsustainable use.

Published
2023

15. Activity of ex vivo graft and DLI Engineering within the last decade increases, a survey from the EBMT Cellular Therapy & Immunobiology Working Party

Author

CTI De Witte, MS Hematologie, Cancer, Infection & Immunity, Regenerative Medicine and Stem Cells, CTI Kuball, de Witte, M A, Mooyaart, J E, Hoogenboom, J D, Chabannon, C, Malard, F, Ruggeri, A, Kuball, J, CTI De Witte, MS Hematologie, Cancer, Infection & Immunity, Regenerative Medicine and Stem Cells, CTI Kuball, de Witte, M A, Mooyaart, J E, Hoogenboom, J D, Chabannon, C, Malard, F, Ruggeri, A, and Kuball, J

Published
2023

16. Impact of KIR/HLA genetic combinations on double umbilical cord blood transplantation outcomes. Results of a French multicentric retrospective study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) and the Société Francophone d’Histocompatibilité et d’Immunogénétique (SFHI)

Author

Rettman, P, Malard, F, Legrand, N, Avinens, O, Eliaou, J-F, Picard, C, Dormoy, A, Lafarge, X, de Matteis, M, Kennel, A, Loiseau, P, Devys, A, Boudifa, A, Absi, L, Fort, M, Masson, D, Quainon, F, Theodorou, I, Batho, A, Parissiadis, A, Delbos, F, Drouet, M, Senitzer, D, Marry, E, Raus, N, Yakoub-Agha, I, Cesbron, A, Retière, C, and Gagne, K

Published
2016
Full Text
View/download PDF

18. Nutrient Dynamics

Author

Tockner, K., Illi, R., Malard, F., Uehlinger, U., Wetzel, Robert G., editor, Ward, J. V., editor, and Uehlinger, U., editor

Published
2003
Full Text
View/download PDF

19. Channel Typology

Author

Tockner, K., Malard, F., Wetzel, Robert G., editor, Ward, J. V., editor, and Uehlinger, U., editor

Published
2003
Full Text
View/download PDF

21. Synthesis and Perspectives

Author

Robinson, C. T., Burgherr, P., Malard, F., Tockner, K., Uehlinger, U., Wetzel, Robert G., editor, Ward, J. V., editor, and Uehlinger, U., editor

Published
2003
Full Text
View/download PDF

26. S236: RANDOMIZED MULTICENTER PHASE III STUDY OF HAPLO VERSUS HLA-MATCHED UNRELATED DONOR (UD) ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO HSCT) FOR PATIENTS OLDER THAN 55 YEARS

Author

Harbi, S., primary, Boher, J.-M., additional, Forcade, E., additional, Chevallier, P., additional, Peffault De Latour, R., additional, Malard, F., additional, Francois, S., additional, Charbonnier, A., additional, Hermet, E., additional, Bulabois, C. E., additional, Huynh, A., additional, Berceanu, A., additional, Cluzeau, T., additional, Rubio, M. T., additional, Furst, S., additional, devillier, R., additional, Mohty, M., additional, and Blaise, D., additional

Published
2022
Full Text
View/download PDF

30. Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients : a position statement from an international expert group

Author

Mohty, M., Malard, F., Abecasis, M., Aerts, E., Alaskar, A.S., Aljurf, M., Arat, M., Bader, P., Baron, F., Basak, G., Bazarbachi, A., Blaise, D., Ciceri, F., Corbacioglu, S., Dalle, J.H., Dignan, F., Fukuda, T., Huynh, A., Kuball, J., Lachance, S., Lazarus, H., Masszi, T., Michallet, M., Nagler, A., NiChonghaile, M., Okamoto, S., Pagliuca, A., Peters, C., Petersen, F.B., Richardson, P.G., Ruutu, T., Saber, W., Savani, B.N., Soiffer, R., Styczynski, J., Wallhult, E., Yakoub-Agha, I., Duarte, R.F., Carreras, Enric, Universitat Autònoma de Barcelona, HUS Comprehensive Cancer Center, Clinicum, Hematologian yksikkö, Mohty, M., Malard, F., Abecasis, M., Aerts, E., Alaskar, A. S., Aljurf, M., Arat, M., Bader, P., Baron, F., Basak, G., Bazarbachi, A., Blaise, D., Ciceri, F., Corbacioglu, S., Dalle, J. -H., Dignan, F., Fukuda, T., Huynh, A., Kuball, J., Lachance, S., Lazarus, H., Masszi, T., Michallet, M., Nagler, A., Nichonghaile, M., Okamoto, S., Pagliuca, A., Peters, C., Petersen, F. B., Richardson, P. G., Ruutu, T., Saber, W., Savani, B. N., Soiffer, R., Styczynski, J., Wallhult, E., Yakoub-Agha, I., Duarte, R. F., Carreras, E., and UAM. Departamento de Medicina

Subjects
Feature, Adult, medicine.medical_specialty, HEPATIC VENOOCCLUSIVE DISEASE, HAPLOIDENTICAL DONOR TRANSPLANTATION, Medicina, 3122 Cancers, Hepatic Veno-Occlusive Disease, Disease, Hematopoietic cell transplantation (HCT), Therapeutics, PERIPHERAL-BLOOD, law.invention, 03 medical and health sciences, 0302 clinical medicine, Polydeoxyribonucleotides, Randomized controlled trial, law, medicine, Humans, Vascular Diseases, Intensive care medicine, Transplantation, Adult patients, business.industry, Mortality rate, Consensus guideline, Hematopoietic Stem Cell Transplantation, REGIMEN-RELATED TOXICITIES, STEM-CELL TRANSPLANTATION, Hematology, Expert group, BONE-MARROW-TRANSPLANTATION, PD-1 BLOCKADE, EUROPEAN-SOCIETY, RANDOMIZED-TRIAL, 3. Good health, URSODEOXYCHOLIC ACID, 030220 oncology & carcinogenesis, Veno-occlusive disease (SOS/VOD, Veno-Occlusive Disease, Complication, business, Haematological diseases, 030215 immunology
Abstract

Sinusoidal obstruction syndrome, also known as veno-occlusive disease (SOS/VOD), is a potentially life-threatening complication that can develop after hematopoietic cell transplantation (HCT). While SOS/VOD may resolve within a few weeks in the majority of patients with mild-to-moderate disease, the most severe forms result in multiorgan dysfunction and are associated with a high mortality rate (>80%). Therefore, careful surveillance may allow early detection of SOS/VOD, particularly as the licensed available drug is proven to be effective and reduce mortality. The aim of this work is to propose an international consensus guideline for the treatment and prevention of SOS/VOD in adult patients, on behalf of an international expert group, This work was made possible thanks to the support of the Association for Training, Education, Research, in Hematology, Immunology and Transplantation (ATHERIT), which received an unrestricted educational grant from JAZZ pharmaceuticals

Published
2021

31. Beneficial role of CD8+T-cell reconstitution after HLA-haploidentical stem cell transplantation for high-risk acute leukaemias

Author

Bondanza, A., Ruggeri, L., Noviello, M., Eikema, D.J., Bonini, C., Chabannon, C., Werf, S. van der, Biezen, A. van, Wreede, L.C. de, Crucitti, L., Vago, L., Merluzzi, M., Massei, M.S., Veelken, H., Koc, Y., Bader, P., Gruhn, B., Locatelli, F., Ciceri, F., Toubert, A., Velardi, A., Bernardo, M.E., Dazzi, F., Ellard, R., Fleischhauer, K., Greco, R., Hudecek, M., Kohl, U., Kuball, J., Malard, F., Pedrazzoli, P., Rocha, V., Ruggeri, A., Urbano-Ispizua, A., Wang, J.F., Wieten, L., EBMT Cell Therapy Immunobiol Worki, Bondanza, Attilio, Ruggeri, Loredana, Noviello, Maddalena, Eikema, Dirk-Jan, Bonini, Chiara, Chabannon, Christian, van der Werf, Steffie, van Biezen, Anja, de Wreede, Liesbeth C., Crucitti, Lara, Vago, Luca, Merluzzi, Mara, Massei, Maria Speranza, Veelken, Hendrik, Koc, Yener, Bader, Peter, Gruhn, Bernd, Locatelli, Franco, Ciceri, Fabio, Toubert, Antoine, Velardi, Andrea, MUMC+: DA TI Laboratorium (9), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, and MUMC+: DA TI Staf (9)

Subjects
Male, Oncology, BLOOD, COUNT, Medizin, CHILDREN, CD8-Positive T-Lymphocytes, DISEASE, 0302 clinical medicine, Risk Factors, hemic and lymphatic diseases, Cytotoxic T cell, Registries, Child, INDEX, Leukemia, Hematology, Middle Aged, RECOVERY, Haematopoiesis, surgical procedures, operative, medicine.anatomical_structure, Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA, Transplantation, Child, Preschool, 030220 oncology & carcinogenesis, HSCT, Female, Stem cell, Adult, medicine.medical_specialty, Adolescent, T cell, Human leukocyte antigen, Young Adult, 03 medical and health sciences, CD8-positive T-lymphocytes, haematopoietic stem cell transplantation, risk factors, Internal medicine, SCORE, medicine, Humans, IMMUNOTHERAPY, Aged, business.industry, ADULTS, BONE-MARROW-TRANSPLANTATION, Transplantation, Haploidentical, business, CD8, Stem Cell Transplantation, 030215 immunology, RESPONSES
Abstract

HLA-haploidentical haematopoietic stem cell transplantation (haplo-HSCT) is increasingly offered to patients with high-risk acute leukaemia. Unfortunately, haplo-HSCT is followed by a delayed immunoreconstitution. The aim of this EBMT registry study was to explore the clinical impact of lymphocyte subset counts after haplo-HSCT. We considered 144 leukaemic patients transplanted in the period 2001-2012. Pre-transplantation clinical variables and differential immune-cell counts (CD3, CD4, CD8 T cells, NK and B cells) measured before day 100 were evaluated for their capacity to predict overall survival, relapse mortality or non-relapse mortality (NRM). Negative prognostic factors for overall survival were advanced disease state at transplantation, host age and CMV seropositivity. Higher CD3, CD4 and CD8 counts were associated with a better overall survival and a lower NRM. Strikingly, when tested in multivariable analysis, higher CD3 and CD8 counts were still significantly associated with a lower NRM. These results indicate that an accelerated T-cell reconstitution correlates with less transplantation mortality, likely due to the protective role of T cells against viral infections. This observation suggests that CD8+ T-cell counts should be investigated as surrogate biomarkers of outcome in prospective haplo-HSCT trials.

Published
2019
Full Text
View/download PDF

34. Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives—a position statement from the European Society for Blood and Marrow Transplantation (EBMT)

Author

Mohty, M, Malard, F, Abecassis, M, Aerts, E, Alaskar, A S, Aljurf, M, Arat, M, Bader, P, Baron, F, Bazarbachi, A, Blaise, D, Ciceri, F, Corbacioglu, S, Dalle, J-H, Duarte, R F, Fukuda, T, Huynh, A, Masszi, T, Michallet, M, Nagler, A, NiChonghaile, M, Pagluica, T, Peters, C, Petersen, F B, Richardson, P G, Ruutu, T, Savani, B N, Wallhult, E, Yakoub-Agha, I, and Carreras, E

Published
2015
Full Text
View/download PDF

38. La fréquence des Slan Monocytes est augmentée et leur capacité fonctionnelle altérée dans la sclérodermie systémique

Author

Eshagh, D., primary, Ricard, L., additional, Siblany, L., additional, De Vassoigne, F., additional, Laurent, C., additional, Beurier, P., additional, Jachiet, V., additional, Malard, F., additional, Riviere, S., additional, Fain, O., additional, Mohty, M., additional, Gaugler, B., additional, and Mekinian, A., additional

Published
2021
Full Text
View/download PDF

42. Correction: Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients (Bone Marrow Transplantation, (2020), 55, 6, (1114-1125), 10.1038/s41409-020-0803-y)

Author

Spyridonidis A., Labopin M., Savani B. N., Niittyvuopio R., Blaise D., Craddock C., Socie G., Platzbecker U., Beelen D., Milpied N., Cornelissen J. J., Ganser A., Huynh A., Griskevicius L., Giebel S., Aljurf M., Brissot E., Malard F., Esteve J., Peric Z., Baron F., Ruggeri A., Schmid C., Gilleece M., Gorin N. -C., Lanza F., Shouval R., Versluis J., Bug G., Floisand Y., Ciceri F., Sanz J., Bazarbachi A., Nagler A., Mohty M., Spyridonidis, A., Labopin, M., Savani, B. N., Niittyvuopio, R., Blaise, D., Craddock, C., Socie, G., Platzbecker, U., Beelen, D., Milpied, N., Cornelissen, J. J., Ganser, A., Huynh, A., Griskevicius, L., Giebel, S., Aljurf, M., Brissot, E., Malard, F., Esteve, J., Peric, Z., Baron, F., Ruggeri, A., Schmid, C., Gilleece, M., Gorin, N. -C., Lanza, F., Shouval, R., Versluis, J., Bug, G., Floisand, Y., Ciceri, F., Sanz, J., Bazarbachi, A., Nagler, A., and Mohty, M.

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Published
2020

45. Infiltrat myéloïde clonal identifié par next generation sequencing dans les lésions cutanées associées aux syndromes myélodysplasiques et leucémies myélomonocytaires chroniques

Author

Martin de Frémont, G., primary, Hirsch, P., additional, Gimenez De Mestral, S., additional, Moguelet, P., additional, Ditchi, Y., additional, Emile, J.F., additional, Senet, P., additional, Georgin-Lavialle, S., additional, Hanslik, T., additional, Maurier, F., additional, Adedjouma, A., additional, Abisror, N., additional, Mahevas, T., additional, Malard, F., additional, Ades, L., additional, Fenaux, P., additional, Fain, O., additional, and Mekinian, A., additional

Published
2021
Full Text
View/download PDF

46. Maladie de Still et PseudoStill associés aux SMD et LMMC : Étude nationale Française

Author

Delplanque, M., primary, Aouba, A., additional, Hirsch, P., additional, Fenaux, P., additional, Graveleau, J., additional, Malard, F., additional, Roos-Weil, D., additional, Belfeki, N., additional, Groh, M., additional, Guillet, S., additional, Razanamahery, J., additional, Mahevas, M., additional, Maigné, G., additional, Miranda, S., additional, Quéméneur, T., additional, Sailler, L., additional, Sebert, M., additional, Terriou, L., additional, Georgin-Lavialle, S., additional, and Mekinian, A., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results